- Home
- KRRO vs EARN Comparison
KRRO vs EARN Comparison
Compare KRRO & EARN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- EARN
- Stock Information
- Founded
- KRRO 2014
- EARN 2012
- Country
- KRRO United States
- EARN United States
- Employees
- KRRO N/A
- EARN N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- EARN Real Estate Investment Trusts
- Sector
- KRRO Health Care
- EARN Real Estate
- Exchange
- KRRO Nasdaq
- EARN Nasdaq
- Market Cap
- KRRO 209.6M
- EARN 187.6M
- IPO Year
- KRRO 2019
- EARN 2013
- Fundamental
- Price
- KRRO $17.41
- EARN $5.42
- Analyst Decision
- KRRO Strong Buy
- EARN Hold
- Analyst Count
- KRRO 7
- EARN 1
- Target Price
- KRRO $132.17
- EARN N/A
- AVG Volume (30 Days)
- KRRO 92.3K
- EARN 789.5K
- Earning Date
- KRRO 03-18-2025
- EARN 03-12-2025
- Dividend Yield
- KRRO N/A
- EARN 17.75%
- EPS Growth
- KRRO N/A
- EARN N/A
- EPS
- KRRO N/A
- EARN 0.28
- Revenue
- KRRO $2,271,000.00
- EARN $15,069,000.00
- Revenue This Year
- KRRO N/A
- EARN $109.38
- Revenue Next Year
- KRRO N/A
- EARN $38.79
- P/E Ratio
- KRRO N/A
- EARN $19.37
- Revenue Growth
- KRRO N/A
- EARN N/A
- 52 Week Low
- KRRO $15.21
- EARN $5.41
- 52 Week High
- KRRO $98.00
- EARN $7.26
- Technical
- Relative Strength Index (RSI)
- KRRO 30.45
- EARN 23.79
- Support Level
- KRRO $16.78
- EARN $5.77
- Resistance Level
- KRRO $25.25
- EARN $5.98
- Average True Range (ATR)
- KRRO 2.92
- EARN 0.15
- MACD
- KRRO -0.25
- EARN -0.01
- Stochastic Oscillator
- KRRO 16.57
- EARN 0.54
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About EARN Ellington Residential Mortgage REIT of Beneficial Interest
Ellington Credit Co is focused on corporate collateralized loan obligations (CLOs). It focuses on acquiring, investing in, and managing secondary CLO mezzanine debt and equity tranches. The company relies on strong risk management, including disciplined liquidity management and selective use of credit hedges, to preserve book value during times of stress. It also leverages Ellington's proprietary technology, analytics and risk management systems to enhance underwriting and investment selection and to guide ongoing portfolio monitoring and surveillance.